Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 49 of 231 for:    CALCITONIN SALMON

Diagnostic Values of C-reactive Protein and Procalcitonin in Predicting Bacterial Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03923803
Recruitment Status : Not yet recruiting
First Posted : April 23, 2019
Last Update Posted : April 23, 2019
Sponsor:
Information provided by (Responsible Party):
Doha Ismail Moussa, Assiut University

Brief Summary:
Chronic obstructive pulmonary disease is a serious disease . Exacerbations of Chronic obstructive pulmonary disease is an acute worsening condition of Chronic obstructive pulmonary disease, which always accompanied by clinical symptoms such as, shortness of breath and increased production of sputum. Respiratory infection (bacteria or viruses or mixed) is thought to be the main cause in most exacerbations.

Condition or disease Intervention/treatment
Chronic Obstructive Pulmonary Disease Diagnostic Test: C- reactive protein Diagnostic Test: Pro calcitonin

Layout table for study information
Study Type : Observational
Estimated Enrollment : 90 participants
Observational Model: Other
Time Perspective: Cross-Sectional
Official Title: Diagnostic Values of C-reactive Protein and Procalcitonin in Predicting Bacterial Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Estimated Study Start Date : July 2019
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Calcitonin

Group/Cohort Intervention/treatment
Chronic obstructive pulmonary disease
patients with acutely exacerbated Chronic obstructive pulmonary disease admitted in chest department Assiut university hospital ,30 patients who revealed sputum culture and inflammatory markers suggesting infection exacerbation will be followed up
Diagnostic Test: C- reactive protein
the measurement will be done by chemileumeniscence

Diagnostic Test: Pro calcitonin
the measurement will be done by chemileumeniscence




Primary Outcome Measures :
  1. The level of C-reactive protein between Infection and Non-infectious inflammatory response in acute exacerbations of Chronic obstructive pulmonary disease patients [ Time Frame: 24 hours ]
    Patients will be classified into cases with Infection or non-infectious inflammatory response according to the level of C-reactive protein



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients with acutely exacerbated chronic obstructive pulmonary disease
Criteria

Inclusion Criteria:

- Patients admitted to the hospital

Exclusion Criteria:

  • patients with malignancies
  • patients with other systemic infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03923803


Contacts
Layout table for location contacts
Contact: Hanan Omar, MD 01223971654 hananomar1962@gmail.com
Contact: Zeinab Ahmed, MD 01003233267 zeinabdoctor@yahoo.com

Sponsors and Collaborators
Assiut University

Layout table for additonal information
Responsible Party: Doha Ismail Moussa, Principal investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03923803     History of Changes
Other Study ID Numbers: CRPPC
First Posted: April 23, 2019    Key Record Dates
Last Update Posted: April 23, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Bacterial Infections
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Calcitonin
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Bone Density Conservation Agents